Baudax Bio's Anjeso Receives the US FDA's Approval to Manage Moderate to Severe Pain
Shots:
- The approval of Anjeso is based on two P-III studies assessing Anjeso (30mg- bolus injection) following Major Surgery and Abdominoplasty Surgery vs PBO in ratio (1:1) in 932 patients
- The study demonstrated well tolerated results- also achieved 15 of the 19 secondary endpoints- plus statistically significant differences in SPID6- SPID12- SPID24- SPID24-48 with no serious adverse events
- Anjeso (meloxicam) injection is a long-acting- preferential COX-2 inhibitor that possess analgesic- anti-inflammatory and antipyretic activities also approved by the US FDA in Feb-2020 for moderate to severe pain- alone or in combination with other non-NSAID analgesics
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com